Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study

被引：0
|
作者：
Felix Hasler
Ulrike Grimberg
Marco A. Benz
Theo Huber
Franz X. Vollenweider
机构：
[1] Psychiatric University Hospital Zürich,Heffter Research Center
来源：
Psychopharmacology | 2004年 / 172卷
关键词：
Psilocybin; Dose–effect study; Psycho(patho)logy; Neuroendocrinology; Cardiovascular effects; Altered states of consciousness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：145 / 156
页数：11
相关论文
共 39 条
  • [31] Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study
    Mori, Etsuro
    Ikeda, Manabu
    Iseki, Eizo
    Katayama, Sadao
    Nagahama, Yasuhiro
    Ohdake, Megumi
    Takase, Takao
    PSYCHOGERIATRICS, 2024, 24 (03) : 542 - 554
  • [32] Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies
    Mori, Etsuro
    Ikeda, Manabu
    Ohdake, Megumi
    PSYCHOGERIATRICS, 2024, 24 (03) : 589 - 596
  • [33] The effect of omega-3 long chain polyunsaturated fatty acids on aggressive behaviour in adult male prisoners: a structured study protocol for a multi-centre, double-blind, randomised placebo-controlled trial and translation into policy and practice
    Meyer, Barbara J.
    Byrne, Mitchell K.
    Cortie, Colin H.
    Parletta, Natalie
    Jones, Alison
    Eckermann, Simon
    Butler, Tony
    Greenberg, David
    Batterham, Marijka
    Fernandez, Francesca
    Schofield, Peter W.
    Winberg, Pia C.
    Bowles, Kate
    Dally, Jean
    Martin, Anne-Maria
    Grant, Luke
    TRIALS, 2021, 22 (01)
  • [34] Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial
    Becker, Anna M.
    Humbert-Droz, Melusine
    Mueller, Lorenz
    Jelusic, Alen
    Tolev, Avram
    Straumann, Isabelle
    Avedisian, Isidora
    Erne, Livio
    Thomann, Jan
    Luethi, Dino
    Gruenblatt, Edna
    zu Schwabedissen, Henriette Meyer
    Liechti, Matthias E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [35] Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial
    Raine, Adrian
    Portnoy, Jill
    Liu, Jianghong
    Mahoomed, Tashneem
    Hibbeln, Joseph R.
    JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2015, 56 (05) : 509 - 520
  • [36] A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial
    Possemis, Nina
    Verhey, Frans
    Prickaerts, Jos
    Blokland, Arjan
    Ramakers, Inez
    TRIALS, 2024, 25 (01)
  • [37] Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
    Erritzoe, David
    Barba, Tommaso
    Greenway, Kyle T.
    Murphy, Roberta
    Martell, Jonny
    Giribaldi, Bruna
    Timmermann, Christopher
    Murphy-Beiner, Ashleigh
    Jones, Michelle Baker
    Nutt, David
    Weiss, Brandon
    Carhart-Harris, Robin
    ECLINICALMEDICINE, 2024, 76
  • [38] Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations
    Kondo, Takayuki
    Banno, Haruhiko
    Okunomiya, Taro
    Amino, Yoko
    Endo, Kayoko
    Nakakura, Akiyoshi
    Uozumi, Ryuji
    Kinoshita, Akemi
    Tada, Harue
    Morita, Satoshi
    Ishikawa, Hidehiro
    Shindo, Akihiro
    Yasuda, Ken
    Taruno, Yosuke
    Maki, Takakuni
    Suehiro, Takashi
    Mori, Kohji
    Ikeda, Manabu
    Fujita, Koji
    Izumi, Yuishin
    Kanemaru, Kazutomi
    Ishii, Kenji
    Shigenobu, Kazue
    Kutoku, Yumiko
    Sunada, Yoshihide
    Kawakatsu, Shinobu
    Shiota, Shunji
    Watanabe, Toshifumi
    Uchikawa, Osamu
    Takahashi, Ryosuke
    Tomimoto, Hidekazu
    Inoue, Haruhisa
    BMJ OPEN, 2021, 11 (06):
  • [39] Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants
    Rucker, James Jonathan
    Roberts, Claire
    Seynaeve, Mathieu
    Young, Allan H.
    Suttle, Ben
    Yamamoto, Takahiro
    Ermakova, Anna O.
    Dunbar, Fiona
    Wiegand, Frank
    JOURNAL OF PSYCHOPHARMACOLOGY, 2024, 38 (08) : 712 - 723
1234